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FibroblastHMG-CoA reductase, the proximal rate-limiting enzyme in the mevalonate pathway, is inhibited by statins.
Beyond their cholesterol lowering impact, statins have pleiotropic effects and their use is linked to improved
lung health. We have shown that mevalonate cascade inhibition induces apoptosis and autophagy in cultured
human airway mesenchymal cells. Here, we show that simvastatin also induces endoplasmic reticulum (ER)
stress and the unfolded protein response (UPR) in these cells. We tested whether coordination of ER stress,
autophagy and apoptosis determines survival or demise of human lung mesenchymal cells exposed to statin.
We observed that simvastatin exposure activates UPR (activated transcription factor 4, activated transcription
factor 6 and IRE1α) and caspase-4 in primary human airway ﬁbroblasts and smooth muscle cells. Exogenous
mevalonate inhibited apoptosis, autophagy and UPR, but exogenous cholesterol was without impact, indicating
that sterol intermediates are involved with mechanismsmediating statin effects. Caspase-4 inhibition decreased
simvastatin-induced apoptosis, whereas inhibition of autophagy by ATG7 or ATG3 knockdown signiﬁcantly
increased cell death. In BAX−/−/BAK−/− murine embryonic ﬁbroblasts, simvastatin-triggered apoptotic and
UPR eventswere abrogated, but autophagyﬂuxwas increased leading to cell death via necrosis. Our data indicate
thatmevalonate cascade inhibition, likely associatedwith depletion of sterol intermediates, can lead to cell death
via coordinated apoptosis, autophagy, and ER stress. The interplay between these pathways appears to be
principally regulated by autophagy and Bcl-2-family pro-apoptotic proteins. These ﬁndings uncover multiple
mechanisms of action of statins that could contribute to reﬁning the use of such agent in treatment of lung disease.
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o).1. Introduction
Statins are inhibitors of HMG-CoA reductase, theproximal effector in
the multistep mevalonate cascade that leads to synthesis of cholesterol
and other sterols [1,2]. HMG-CoA reductase inhibition depletes cells of
lipid intermediates, an effect that limits the availability of isoprenoid,
substrates needed for posttranslational protein lipidation. This modiﬁ-
cation controls activation state, stability and sub-cellular distribution
of many proteins in signaling pathways that regulate cell growth,
survival, differentiation and synthetic function [3].
Statins have emerged as compounds with pleiotropic inhibitory
effects on inﬂammation, oxidative stress, and tissue repair; impact
that is linked with positive health outcomes that go beyond serum
lipid-lowering in several conditions, including lung function in the
aged and in smokers as well as in patients with respiratory tract
1260 S. Ghavami et al. / Biochimica et Biophysica Acta 1843 (2014) 1259–1271infection and pneumonia [4,5]. Conversely positive impact of statin use
on asthma symptoms is equivocal [6]. At a cellular level, statins have
broad effects, for instance, we and others reported the suppression of
human airway mesenchymal cell proliferation and synthesis of extra-
cellular matrix proteins, as well as promoting autophagy and apoptosis
at some concentrations [7–9]. Given the diverse effects of statins both
on lung health and on the function of lung mesenchymal cells that
modulate tissue repair, better understanding of their impact at a cellular
level is needed to appreciate potential for treating lung disorders.
The ability of cells to respond to perturbations in endoplasmic
reticulum (ER) function, or ER stress, is critical for cell survival. The
ER is the primary intracellular site for folding and bio-assembly of
membrane-associated and secreted proteins. Within the cell, ER stress
is sensed by three upstream signaling proteins, PERK, IRE1 and ATF6,
that upon release from the luminal ER binding protein, BIP, initiate
intracellular transcriptional and translational activity known as
the unfolded protein response (UPR) [10,11]. The UPR is aimed at
reestablishing ER homeostasis; however, if UPR mechanisms of adapta-
tion are insufﬁcient to decrease the unfolded protein load, UPR can
initiate apoptosis leading to cell death [12–14]. In addition to apoptosis,
autophagy may also be triggered by ER stress via the UPR stress sensors
IRE1α and PERK [15,16].
In addition to evidence in different cell types that mevalonate
cascade inhibition can induce apoptosis and autophagy [7, 17–21], the
induction of ER stress has been documented in macrophages [22];
whether mevalonate cascade inhibition with statins leads to a concom-
itant ER stress response in human airway mesenchymal cells in not
known. In the present study, we investigate the effect of simvastatin
exposure on ER stress and the UPR in primary cultured human airway
ﬁbroblasts and smooth muscle cells. Furthermore, we investigate the
degree of interplay that exists between mevalonate cascade inhibition-
induced apoptosis, autophagy and ER stress and how this impacts cell
survival or demise. These studies extend our previous work and shed
needed understanding of the complex cellular response to statins that
may be at the root of the impact of these compounds on lung health.
2. Material and methods
2.1. Reagents
Cell culture plastic ware was obtained from Corning Costar Co.
(Canada). Cell culture media, simvastatin, mevalonate, 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) (MTT), rabbit
anti-human/mouse/rat LC3β, and cholesterol were obtained from
Sigma (Sigma-Aldrich, Oakville, CA). Z-LEVD-FMK is purchased from
Calbiochem (Canada). Rabbit anti-human cleaved caspase-7, -3, rabbit
anti Bak, Bax, GRP78 (BIP), IRE1α, and Atg5 were purchased from Cell
Signaling (Canada). Mouse anti-glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was obtained from Santa Cruz Biotechnologies (USA).
Rabbit anti-ATF6, anti-ATF4, anti-XBP1, anti-Caspase-4, and anti-
Caspase-12, were obtained from Abcam (USA). ATP luminescence assay
kit (Abcam, Canada). Caspase Glo Kit (Caspase-9, -3/-7) (Promega, USA).
2.2. Primary HASM and HAF cell culture preparation
For all experiments we used primary cultured human airway
smooth muscle (HASM) cells and airway ﬁbroblasts (HAF) that were
prepared from 2nd to 4th generation of bronchi in macroscopically
healthy segments of resected lung specimens. After microdissection to
separate submucosal compartments from airway smooth muscle, HAF
and HASM cells respectively, were isolated by enzymatic dissociation
as described [7,20,23,24]. All procedures were approved by the Human
Research Ethics Board (University of Manitoba). Cells were grown in
Dulbecco's modiﬁed Eagle's medium supplemented with 10% fetal
bovine serum with antibiotic. For all experiments cells were starved in
0.5% fetal bovine serum for 48 h prior to all treatments. Medium waschanged every 48 h. For all experiments passages 3–7 of HASM and
HAF were used.
2.3. HASM immortalisation
HASM immortalisation has been done according to our previous
established method [25]. Brieﬂy HASM cells were infected with a retro-
virus vector encoding the hTERT gene. Later hTERT expression cassette
was cloned intopLXIN (Clontech), and replication-incompetentMoloney
murine leukemia virus retrovirus was generated in HEK293 retroviral
packaging cells. Primary and ﬁrst-passage cultures of human airway
smooth muscle cells were infected with the hTERT retrovirus and
selected with 100 mg/ml G418 for 1 wk. Infection was veriﬁed in
immortalised cells by RT-PCR using telomerase-speciﬁc primers. There
is no evidence of senescence up to 60 passages. For all experiments,
passages 10–20 were used.
2.4. MTT assay
Cytotoxicity of simvastatin towards the HASM and HAF was
determinedbyMTT-assays as previously described [7]. In experiments in-
vestigating the effect of mevalonate (0–2 mM), cholesterol (0–50 μM),
and Z-LEVD-FMK, HASM were pre-treated with indicated concentra-
tions of the inhibitors or chemicals (4 h) and then co-treated with indi-
cated concentrations of simvastatin for the experimental time points.
2.5. Apoptosis measurement
Apoptosis wasmeasured using the Nicoletti methodwhich has been
previously used by our group [20,26]. Brieﬂy, HASM grown in 12 well
plates were treated with simvastatin (10 μM) for 72 h, after craping,
cells were harvested by centrifugation at 1500 g, 4 °C, for 5 min. The
cells were washed once with PBS, and then resuspended in a hypotonic
PI lysis buffer (1% sodium citrate, 0.1% Triton X-100, 0.5 mg/ml RNase A,
40 μg/ml propidium iodide). Cell nuclei were then incubated for 30min
at 30 °C and the nuclei were subsequently analyzed by ﬂow cytometry.
Nuclei to the left of the G1 peak containing hypodiploid DNAwere con-
sidered to be apoptotic.
2.6. Immunoblotting
HASM, HAF, immortalised HASM, and different MEF knock out
models were treated with indicated dose of simvastatin, in each time
point attached andﬂoating cellswere collected in control and simvastatin
treated cells. Western blotting was used to detect cleaved caspase-3, -7,
ATF6, caspase-12, caspase-4, ATF4, IRE1α, Atg5–12, LC3β, XBP1,
HMGB1, beta actin, and GAPDH. Brieﬂy, cells were washed and protein
extracts prepared in lysis buffer (20 mM Tris–HCl (pH 7.5), 0.5%
Nonidet P-40, 0.5 mM PMSF, 100 μM β-glycerol 3-phosphate and 0.5%
protease inhibitor cocktail). After centrifugation at 13,000 ×g for
10 min, protein content in the supernatant was determined by Lowry
protein assay, proteins were then size-fractionated by SDS-PAGE and
transferred onto nylon membranes under reducing conditions. After
blocking membranes with non-fat dried milk and Tween 20, blots
were incubated overnight with the primary antibodies at 4 °C. HRP-
conjugated secondary antibody incubation was for 1 h at room temper-
ature (RT), then blotswere developed by enhanced chemiluminescence
(ECL) detection (Amersham-Pharmacia Biotech) [7].
2.7. Caspase luminometric assay
Caspase-9, and caspase-3/-7 activity wasmeasured using a lumines-
cence based assay (Promega, CA) based on previously established
method [27]. Brieﬂy MEF WT, ATG3 KO, and Bax/Bak KO were cultured
in 96 well plates (5000 cells per well). After being 65 conﬂuent, they
were treated with simvastatin (10 μM) and in the proper time point
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2.8. Electron microscopy
HASM, HAF, immortalised HASM, and different MEF knock out
models were treated with indicated dose of simvastatin, in each time
point attached and ﬂoating cells were collected in control and simva-
statin treated cells. For transmission electron microscopy (TEM), cells
were ﬁxed (2.5% glutaraldehyde in PBS (pH 7.4) for 1 h at 4 °C) and
post-ﬁxed (1% osmium tetroxide) before embedding in Epon. TEM
was performed with a Philips CM10, at 80 kV, on ultra-thin sections
(100 nm on 200 mesh grids) stained with uranyl acetate and counter-
stained with lead citrate [7].
2.9. Stable gene silencing by lentiviral delivery of shRNA
ATG7-shRNA lentiviral particles (sc-41447-V) and control shRNA
lentiviral particles (sc-108080) were purchased from Santa Cruz
Biotechnology (US). For infection, immortalised HASM cells were grown
to 70% conﬂuence and transduced at an MOI of 10 in the presence
of 30 μg/mL polybrene (ﬁnal concentration) overnight. Excess viral
vectors were removed and the transduced cells were cultured in fresh
medium for 2 days before selection of stable expression of shRNA by
growing in culture media containing puromycin (4 μg/mL) for at least
3 weeks. For control cells, a GIPZ vector harboring “scrambled” non-
coding shRNA was prepared and used to generate lentivirus for trans-
duction of the same primary HASM cell lines that were used to generate
ATG7-deﬁcient stable cultures.
2.10. Sub-cellular fractionation
Following induction of cell death using simvastatin (10 μM)cytosolic,
mitochondrial and nuclear fractions were generated using a digitonin-
based subcellular fractionation technique as described previously [20].
Brieﬂy, 107 cells were harvested by centrifugation at 800 ×g, washed
in phosphate buffered saline (PBS) pH 7.2, and re-pelleted. Cells were
digitonin-permeabilised for 5 min on ice at a density of 3 × 107/ml in
cytosolic extraction buffer (250 mM sucrose, 70 mM KCl, 137 mM NaCl,
4.3 mM Na2HPO4, 1.4 mM KH2PO4 pH 7.2, 100 μM PMSF, 10 μg/ml
leupeptin, 2 μg/ml aprotinin, containing 200 μg/ml digitonin). Plasma
membrane permeabilisation of cells was conﬁrmed by staining in a
0.2% trypan blue solution. Cells were then centrifuged at 1000 ×g for
5 min at 4 °C. The supernatants (cytosolic and mitochondria fractions)
were saved and pellets solubilised in the same volume of nuclear lysis
buffer, followed by pelleting at 12,500 ×g for 10 min at 4 °C.
2.11. HMGB1 release
HMGB1 release was assessed by immunoblot analysis. Cells were
seeded in 100 mm dishes. After 24 h (80% conﬂuence), cells were treat-
ed with simvastatin (10 μM) and at the indicated time point (72 h) the
supernatant was collected, centrifuged in 10,000 ×g for 20 min, trans-
ferred to 50 ml ﬁlter tubes (10 kD mesh, Amicon), and centrifuged in
3000 ×g for 35 min. The remaining supernatant on top of the ﬁlter
was collected and Western blot analysis was performed using a rabbit
anti-HMGB1 antibody (Abcam, Canada).
2.12. ATP assay
Abcam's ATP assay kit was used tomeasure ATP. Brieﬂy theAssay Kit
(Bioluminescent) utilises bioluminescent detection of ATP levels for a
rapid screening of apoptosis, necrosis, growth arrest, and cell prolifera-
tion simultaneously in mammalian cells. The assay utilises the enzyme
luciferase to catalyze the formation of light from ATP and luciferin,
and the light can be measured using a luminometer [28].2.13. Statistical analysis
Results were expressed as means ± SDE and statistical differences
were evaluated by one-way or two-way ANOVA followed by Tukey's
or Bonferroni's post hoc test, using Graph Pad Prism 5.0. P b 0.05 was
considered signiﬁcant. For all experiments data were collected in tripli-
cates from at least three cell lines unless otherwise indicated.
3. Results
3.1. Loss of cholesterol intermediates triggers simvastatin-induced cell death
We and others have shown that inhibition of mevalonate synthesis
by statins can activate autophagy, apoptosis, and UPR in different cells
[7,20,22,26,29]. We have also recently showed that simvastatin induces
cell death in both HASM and HAF [7,20]. Here we assessed whether cell
death induced by mevalonate cascade inhibition in HASM could be
prevented by the addition of exogenous mevalonate and conﬁrmed
that depletion of intermediate cascade lipid moieties is the likely
cause of cytotoxicity (Fig. 1A & D). Simvastatin induced apoptosis was
also conﬁrmed using PI based FACS assay (Fig. 1B). Of note, addition of
exogenous cholesterol (0–50 μM) to cells treated with simvastatin had
no impact on cell viability, indicating that depletion of cellular choles-
terol per se did not invoke cell death (Fig. 1C). To decipher intracellular
responses associated with mevalonate cascade inhibition, we used
immunoblotting to track abundance of: lipidated LC3β II, a marker for
autophagy [30], cleaved caspase-3 and PARP-1, markers for apoptosis
[27], as well as, UPR markers BIP, activating transcription factor 4
(ATF4), cleaved activating transcription factor 6 (ATF6), and spliced X
box-binding protein1 (sXBP1) [26,31]. In simvastatin-treated HASM
cells, mevalonate (2 mM) signiﬁcantly blunted hallmarks of autophagy
and UPR, as well as protecting again loss of PARP-1 whilst inhibiting
cleaved caspase-3 accumulation (apoptosis markers). These observa-
tions indicate that lipid intermediate depletion is a critical determinant
of a multi-faceted cell response to simvastatin (Fig. 1E–K). As the
response of primary HASM and HAF to simvastatin is following the
same trends in apoptosis, UPR, and autophagy we used primary HASM
cells and senescence-resistant cell lines generated from them in the sub-
sequent experiments. On the other hand in some experiments we used
MEFs in our work exclusively as a tool for proof-of-principle related to
mechanisms that are suggested fromour experiments usingHASMcells.
3.2. Mevalonate cascade inhibition activates UPR in airway mesenchymal
cells
As our initial experiments indicated that markers for UPR are
concomitantly activated with those for apoptosis and autophagy, we
more rigorously assessed simvastatin-induced UPR in human airway
mesenchymal cells. UPR is driven by the activation of ER resident
proteins including IRE1α (inositol-requiring protein1 α), the protein
chaperone BiP (immunoglobulinbinding protein; Grp78), CHOP, ER
oxidase1α (Ero1α) and calnexin [10,31–33]. Under conditions where
ER stress mediates cell death and apoptosis, ER-located caspase-12
also activates UPR signaling [34,35]. Our experiments assessed the
degree to which the abundance of UPR effectors are impacted in HAF
and HASM cells by simvastatin (10 μM, 0–120 h) (Fig. 2A–G). Western
blotting and densitometry revealed that mevalonate cascade inhibition
induced a rapid increase of Ero1α and calnexin as well as caspase-4
activation, with subsequent accumulation of CHOP, BIP and IRE1α.
These data conﬁrm that simvastatin induces UPR, and its individual
effectors are activated with different kinetics.
We next examined the impact of mevalonate cascade inhibition on
several transcription factors that promote UPR, including spliced XBP1,
ATF6 and ATF4. These factors regulate genes encoding CHOP, p58IPK,
and proteins involved in amino acid transport and synthesis, stress
responses, redox reactions and protein degradation [31,36,37].
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induced by IRE1α, whereas during ER stress ATF6 is cleaved prior to
nuclear localisation, and ATF4 is activated by PERK [36,37]. Consistent
with these mechanisms, using cell fractionation and immunoblot anal-
ysis we observed that mevalonate cascade inhibition (simvastatinA
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cleaved ATF6 concomitant with PERK phosphorylation (Fig. 2H). These
ﬁndings conﬁrm that the three main signaling arms of UPR (IRE1α,
PERK, and ATF6) are activated in response to simvastatin treatment in
primary cultured human airway mesenchymal cells.B
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Fig. 1.Mevalonate inhibits simvastatin-induced cell death response including ER-stress, autophagy, and apoptosis. (A) HASMcells were treatedwith simvastatin (10 μM) and cell viability
was assessed 72 and 120 h thereafter by MTT assay. Control cells for each time point were treated with the solvent control (DMSO) at the same concentration. Results are expressed as
percentage of corresponding time point control and represent the means ± SD of 6 independent experiments in three different HASM (★★★ P b 0.001). (B) HASM cells were treated
with simvastatin (10 μM), ﬂoating and attached cells were collected and apoptosiswas assessed 72 h thereafter by propidium iodide FACS assay (Nicolleti). (C) Effects of supplementation
with cholesterol (0–50 μM) on HASM cell death, 4 h prior to treatment with simvastatin (10 μM, 96 h) on simvastatin-induced cell death. For each experiment control cells were treated
with simvastatin solvent (DMSO) alone (control) orwith bothDMSOand the appropriate solvent (ethanol). Results are expressed asmean±SDof 6 independent experiments using three
different HASM primary cells. (C) Effects of supplementationwith 2mMmevalonate evaluate on cell death, 4 h prior to treatment with simvastatin (10 μM, 96 h) on simvastatin-induced
cell death. For each experiment control cells were treated with simvastatin solvent (DMSO) alone (control) or with both DMSO and the appropriate solvent (ethanol). Results are
expressed asmean± SDof 6 independent experiments using three differentHASMprimary cells (★★★ P b 0.001). The results also indicated that therewas not any signiﬁcant difference
between mevaloante control and simvastatin and mevalonate cotreatment (P N 0.05). (E) Mevalonate inhibited simvastatin-induced (10 μM) autophagy, UPR response, and apoptosis.
Immunoblotting of autophagy (LC3β), UPR (BIP, ATF, cleaved ATF6, spliced XBP1, and IRE1α) and apoptosis (cleaved PARP1 and caspase-3) conﬁrmed the inhibitory effect of mevalonate
on simvastatin-induced autophagy, UPR, and apoptotic response. Results are representative of three different primary HASM. Protein loading was checked using GAPDH protein.
(F–K) Densitometry analysis conﬁrms that mevalonate signiﬁcantly (★★★ P b 0.001) decrease simvastatin (10 μM) induced autophagy (LC3β II/LC3β I, F), and endoplasmic reticulum
stress (BIP, ATF4, sXBP, IRE1α, c-ATF6 G, H, I, J, K respectively).
1263S. Ghavami et al. / Biochimica et Biophysica Acta 1843 (2014) 1259–12713.3. Caspase-4 mediates simvastatin-induced apoptosis and cell death in
human airway smooth muscle cells
As we observed parallel activation of UPR and apoptosis during
simvastatin exposure, we investigated whether these responses were
linked or mutually exclusive. Several reports indicate that UPR-
induced apoptosis is, in part, dependent on the activation of caspase-
4/-12 [38–41]. Since caspase-12 is only present in about 20% of individ-
uals of African descent, we assessed the impact of inhibiting caspase-4
activity using Z-LEVD-FMK (25 μM) (Fig. 3). We found that bothmevalonate cascade inhibition-induced cell death and activation of
caspase-3/-7 were markedly blunted by caspase-4 inhibition. This
observation suggests that simvastatin-induced apoptosis may occur as
the result of UPR that leads to caspase-4 activation.
3.4. Autophagy limits simvastatin-induced apoptosis and UPR
In addition to interplay between apoptosis and UPR, a functional
relationship exists between autophagy and ER stress [42]. Indeed,
autophagymay serve as amechanism to eliminate portions of damaged
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Our group has recently shown that coordination of autophagy and apo-
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Fig. 3. Speciﬁc ER-dependent caspase inhibition reduced mevalonate cascade inhibition-
induced cell death and caspase-3/-7 activation. Primary HASM were pre-treated with
caspase-4 (Z-LEVD-FMK) inhibitor (25 μM) for 4 h and then co-treated with simvastatin
for 96 h. Caspase-4 inhibition not only decreased simvastatin-induced cell death (A) but
also decreased simvastatin-induced caspase-3/-7 activation (B). Results are expressed as
mean ± SD of 4 independent experiments using three different primary HASM cells
(★★★ P b 0.001).
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(KD) of Atg3 and Atg7 inhibits autophagy [7,43,44], we used ATG3 KO
mouse embryonic ﬁbroblasts (MEF) as well as employing shRNAmedi-
ated Atg7 KD in immortalised human airway smooth muscle cells. We
found that cell death triggered by mevalonate cascade inhibition (sim-
vastatin 10 μM, 0–96 h) was signiﬁcantly increased in ATG3 KO MEFs
(Fig. 4A). Similarly, simvastatin more profoundly increased both the
apoptotic response (caspase-7 cleavage, western blot and caspase-3/-7
luminometric assay) and UPR (IRE1α expression) in ATG3 KO MEFs
(Fig. 4B&C). In Atg7 KD human airway smoothmuscle cells, mevalonate
cascade inhibition augmented cell death (Fig. 4D) as well as increasing
caspase-3 cleavage in concert with signiﬁcantly augmented IRE1α
expression when compared to control cells (Fig. 4E) (as Atg7 KD
cells was produced from immortalised HASM (hTERT) cell viability in
Fig. 4D showed slightly difference fromHASMcellswhichwas previously
showed in Fig. 1A). These data indicate that autophagy modulates both
apoptosis and UPR induced bymevalonate cascade inhibition. Moreover,
inhibiting autophagy increases cytotoxic effects of simvastatin in human
airway smooth muscle cells.
3.5. Pro-apoptotic BH3-only proteins coordinate cell death pathways in
response to simvastatin
Our prior work shows that apoptosis induced by mevalonate
cascade inhibition in primary human airway mesenchymal cells is
mediated, in part, by the BH3 only pro-apoptotic proteins, Bax and
Bak [20]. Of note, Bax and Bak, which are partially localised on the ER
membrane, undergo changes in conformation and oligomerise to com-
mit a cell to apoptosis; during ER stress these proteins can be further
impacted, leading to greater damage to ER membranes [45,46]. On this
basis we aimed to determine whether Bax and Bak play a coordinating
role in the multifaceted cellular response that we observe upon simva-
statin exposure. We used MEFs from wild type (WT) and BAX/BAK
double knockout mice and assessed cytotoxic effects 24–72 h after sim-
vastatin (10 μM) exposure (Fig. 5A–C). Using phase contrastmicroscopyFig. 2.Mevalonate cascade inhibition induces UPR expression and translocation of UPR-induce
pairs of HASM and HAF. Cells were treated with 10 μM simvastatin for the indicated time perio
BIP, IRE1α, Ero1, calnexin, and CHOP expression and activated caspase-4. Protein loading was c
on the results of western blot of matched pairs of HASM and HAF which were treated with 10
IRE1α, Ero1, calnexin, and CHOP expression and activated caspase-4 compared (C to G res
(H) Simvastatin (10 μM, 0–72 h) induced ATF4, cleaved ATF6, and spliced XBP1, translocatio
nuclear/cytosolic expression of each protein was evaluated using immunoblotting. Loading andwe observed excessive cell rounding and detachment in BAX−/−/
BAK−/−MEFs (24 h), a response that was consistent with statistically
signiﬁcant greater loss of cell viability (48 and 72 h), as determined
byMTT assay. Paradoxically, these data suggest that cell viability is com-
promised in the absence of a functional Bax/Bak pathway that we have
shown promotes apoptosis upon simvastatin exposure [20].
To more fully understand this response we used immunoblotting
to track hallmark markers of apoptosis, UPR and autophagy after
mevalonate cascade inhibition. We observed that a BAX−/−/BAK−/−
background inhibits both apoptosis (reduced PARP-1 cleavage) and
UPR (reduced expression of BIP and IRE1α). In contrast, absence of
Bax and Bak was associated with excess autophagy, as evident by
increased LC3βII and Atg5–12 conjugation compared to WT cells
(Fig. 5D). We also showed that simvastatin (10 μM, 24 h) induced
signiﬁcant activation of caspase-9 in MEF WT cells while in BAX−/−/
BAK−/−MEF cells caspase-9 was not activated (Fig. 5E). These observa-
tions indicate that in the absence of a functional mitochondrial-
apoptosome pathway, exaggerated autophagy, but reduced apoptosis
and UPR, correlates with compromised cell viability in the presence of
simvastatin.
We next investigated the nature of simvastatin-induced cell death in
BAX−/−/BAK−/− cells. Firstwe used TEM to assess cellular ultrastructure
and observed, particularly in BAX−/−/BAK−/− MEFs, evidence for cell
swelling and rupture, features associatedwith cells undergoing necrosis
(Fig. 5F–G). To better determine whether simvastatin induced necrosis,
wemeasured the level of cellular ATP, which is depleted during necrosis
[47].We found thatmevalonate cascade inhibition induced a signiﬁcant
decrease in ATP content exclusively in BAX−/−/BAK−/−MEFs (Fig. 5H).
The release of the alarmin, High Mobility Group Box 1 (HMGB1), is
another marker of necrosis [48], thus we also used immunoblotting of
concentrated cell culturemedia tomonitor HMGB1 release after simva-
statin treatment (10 μM, 72 h). We determined that HMGB1 was
released exclusively from BAX−/−/BAK−/− cells (Fig. 5I). Taken together,
our experiments demonstrate that though mevalonate cascade inhibi-
tion in the absence of pro-apoptotic Bax and Bak is associated with
limited ER stress, cells undergo exaggerated autophagy that is associated
with cell death via necrosis. These observations also emphasise a role
for BH3 only pro-apoptotic proteins in mitochondria and the ER for
simvastatin-induced ER-stress and apoptosis.
4. Discussion
Statin use has been linkedwith improved lung health, particularly in
COPD patients, but allergen challenge murine models suggest this may
also be the case in asthma, despite small clinical trials in asthmatics
that have been equivocal with respect to patient beneﬁt [5,6]. The
mechanisms for these effects, or lack thereof, are not fully appreciated.
Though statin use is linked with a signiﬁcant anti-inﬂammatory impact
at the systemic level, emerging in vitro data strongly indicate that they
have broad effects on cell growth, survival and synthetic function [3,4,
20]. The present study reveals the degree of complexity in cell response
that can result from mevalonate cascade inhibition and suggests this
may be a reason that the impact of statins at a (patho)physiological
and patient symptom level can be variable. We demonstrate for the
ﬁrst time that human airwayﬁbroblasts and smoothmuscle cells exhibit
ER stress and UPR upon statin exposure. Moreover, these processes are
integrated with pathways that regulate apoptosis and autophagy. We
further demonstrate that BH3-only pro-apoptosis proteins (Bax and
Bak) that associate with the ER and mitochondria are pivotald transcription factors to nucleous. (A) Western blot analysis of cell lysates from matched
ds, and then immunoblotted using the indicated speciﬁc antibodies. Simvastatin provoked
hecked using GAPDH protein. (C–G) Densitometry analysis of UPR proteins has been done
μM simvastatin for the indicated time periods. The results show the fold of increase of BIP,
pectively) to time matched control after normalizing against GAPDH loading control.
n to nucleus. Primary HASM were treated with indicated simvastatin concentration and
fraction purity were conﬁrmed using HDAC protein.
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Fig. 4. Autophagy inhibition increased mevalonate cascade-induced cell death—study in knockdown and knockout models. (A) Wt MEF and ATG3 KO were treated with simvastatin
(10 μM, 96 h). We observed signiﬁcant differences between Wt and ATG3 KO cell in simvastatin-induced cell death (★★★ P b 0.001). For each experiment control cells were treated
with simvastatin solvent (DMSO) at the same concentration. Results are expressed asmean± SD of 6 independent experiments. (B)WtMEF and ATG3 KOwere treated with simvastatin
(10 μM,48 h). Caspase-3/-7 activitywasmeasured in time-matched control and simvastatin treated cells.We observed signiﬁcant differences betweenWt andATG3KOcell in simvastatin-
induced caspase-3/-7 activation (★★★ P b 0.001) (C) Immunoblot analysis showed that mevalonate cascade inhibition in ATG3 KO MEF cells inhibited LC3 lipidation and increased
caspase-7 cleavage and IRE1α expression. Equal protein loading was conﬁrmed using β-actin. (D) Immortalised human airway smoothmuscle (Wt) and ATG7 KOwere treatedwith sim-
vastatin (10 μM, 96 h).We observed signiﬁcant differences betweenWt and ATG3 KO cell in simvastatin-induced cell death (★★ P b 0.01). For each experiment control cells were treated
with simvastatin solvent (DMSO). Results were expressed as mean ± SD of 6 independent experiments. (E) Immunoblot analysis showed that mevalonate cascade inhibition in human
immortalised smooth muscle ATG7 KO cells inhibited LC3 lipidation and increased caspase-3 cleavage and IRE1α expression. Protein loading was checked using GAPDH protein.
1266 S. Ghavami et al. / Biochimica et Biophysica Acta 1843 (2014) 1259–1271determinants in the coordination of the ﬁnal cell response. This under-
standing is important in light of the untapped potential of statins and
other therapeutics that can impact protein lipidation or effectors down-
stream from signaling proteins that are regulated by post translational
lipidation.Though our study is the ﬁrst to describe the activating effects of
mevalonate cascade inhibition on ER stress and UPR in human airway
mesenchymal cells, studies using different cell models have generated
diverse data [22,49–51]. For instance, while some studies reveal statins
to have inhibitory impact on ER stress in the heart of C57BL/6J male
1267S. Ghavami et al. / Biochimica et Biophysica Acta 1843 (2014) 1259–1271mice, and mice macrophages [50,51], but other studies using animal
models of abdominal aortic aneurysm indicate no impact on ER stress
[52]. Notably, as we observed in our current studies with human lung
mesenchymal cells, UPR is activated by statin exposure in RAW264.7
macrophages and K562 cells [22,53]. Apart from subtle differences in
the experimental design, these reports and our work suggest that cell
type-speciﬁc effects may exist with respect to regulatory mechanisms
involving intermediates of the mevalonate cascade on signaling path-
ways that can modulate ER stress and UPR. On this basis the data from
our study using human lung airway mesenchymal cells may be of
importance in understanding the impact of statins on lung health and
disease.
The UPR is a highly conserved, multi-pathway survival mechanism
designed to restore cellular homeostasis in cells subjected to unfavor-
able environmental conditions that perturb ER function and the produc-
tion of properly folded proteins leading to ER stress [31,54]. ER stressControl 
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(H) Simvastatin induced a signiﬁcant (★★★ P b 0.001) decrease in total cellular ATP in BAX
were treated with simvastatin solvent (DMSO) as a control. Results are expressed as mean ± S
with simvastatin (10 μM, 72 h) and concentrated supernatant of these cells were immunoblotte
MEF cells.triggers pathways that attenuate protein synthesis rate and up regulate
activity of genes that encode proteins involved in folding, retro-
translocation and proteasomal degradation of ER-localised proteins
[55,56]. There are three main ER trans-membrane proteins that act as
stress sensors to initiate different UPR signaling cascades: double-
stranded RNA-activated protein kinase (PKR)-like endoplasmic reticu-
lum kinase (PERK), activating transcription factor 6 (ATF6) alpha and
beta, and inositol requiring kinase 1 (IRE1) alpha and beta [14]. Activa-
tion of PERK is mediated by its oligomerisation and autophosphoryl-
ation, leading to ATF4 translation [57], while IRE1α activation leads to
splicing of XPB1 to generate sXBP1 [31,58]. Notably, HMG-CoA reductase
is anchored in the ER membrane [59], thus it is intriguing to speculate
that this subcellular localisation may be permissive to statin induction
of UPR sensor proteins in airway ﬁbroblasts and smooth muscle cells.
Our results show that mevalonate cascade inhibition induces different
arms of the UPR with different kinetics, with early activation of ERSimva 10 M 
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µ
esence of apoptosis and UPR inhibition and necrosis induction. BAX/BAKWtMEF cells and
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/−MEF cells conﬁrmed that simvastatin (10 μM, 72 h) treatment induced autophagosome
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1268 S. Ghavami et al. / Biochimica et Biophysica Acta 1843 (2014) 1259–1271chaperone-like proteins, calnexin and Ero1, and late activation of the ER
stress pathways involving IRE1, ATF6 and ATF4. This suggests that
mevalonate cascade inhibition-induced UPR is a multi-step process.
The precise upstream mechanisms for the impact of simvastatin on
apoptosis, autophagy and ER stress are not fully evident from our
study; however, that we did observe rescue from these pathways with
mevalonate replacement suggests that depletion of intermediates of
the mevalonate cascade is a principal driver. Consistent with this
conclusion, cholesterol supplementation was not sufﬁcient to prevent
statin induction of these pathways and the resulting loss of cell viability.
Indeed in a prior study we conﬁrmed that in conditions similar to those
used in the present study, though simvastatin suppresses HMG-CoA
reductase activity, it does not lead to loss of total cellular cholesterolin human airway mesenchymal cells. These observations offer clues to
highlight the importance of lipid modiﬁcation of protein effectors,
such as small GTPase proteins that require prenylation with C-15
farnesyl or C-20 gernylgeranyl moieties, that are compromised during
statin exposure [20,26]. This suggests that future research effort to
assess the impact of selective inhibitors of prenyltransferases, which
catalyze the prenylation of intracellular proteins, warrant investigation
with respect to lung mesenchymal cell apoptosis, autophagy, UPR and
cell fate.
Our data demonstrate a number of coordinated intracellular
responses to statin exposure that determine cell death and survival.
The triggering of ER stress and UPR activation has been associated
previously with caspase-4 mediated activation of caspase-9 and the
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1269S. Ghavami et al. / Biochimica et Biophysica Acta 1843 (2014) 1259–1271induction of apoptosis [40]. Our data reveal the involvement of caspase-4
in mevalonate cascade inhibition-induced cell death, as a speciﬁc
inhibitor of caspase-4 suppressed simvastatin-triggered effector
caspase activation and prevented loss of cell viability. We recently
reported that concomitant induction of autophagy tempers statin-
triggered apoptosis in human airwaymesenchymal cells [7]. Autophagy
eliminates damaged organelles [60] and cytosolic compounds to
maintain cellular homeostasis and is protective during cellular stress
(e.g. nutrient deﬁciency), thus, preventing cell death, including that
stemming from ER stress [61–70]. Here we show that loss of cell
viability induced by mevalonate cascade inhibition in MEFs and
human airway smooth muscle cells is potentiated by silencing of pro-
autophagy genes, ATG3 or ATG7. Notably, this effect coincided with an
increase in both UPR (IRE1α) and apoptosis markers (cleaved caspase-
3 and -7). Thus, autophagy induced by mevalonate cascade inhibition
modulates both the induction of apoptosis and ER stress that leads to
UPR.
Bcl-2 family members, major regulators of apoptotic signaling, can
localise to the ER and initiate ER damage that modulates apoptotic
pathways linked to mitochondria and the ER [71–73]. Bax and Bak are
pro-apoptotic Bcl-2 family members that are necessary and sufﬁcient
to mediate intrinsic apoptosis pathways triggered by diverse stimuli
[74]. We have previously shown that Bax and Bak regulate mevalonate
cascade inhibition-induced apoptosis in lung mesenchymal cells [20].
Here, using MEFs deﬁcient in both Bax and Bak, we investigated thedependence of ER stress, apoptosis, and autophagy induced by simva-
statin on these proteins. As expected, apoptosis was blunted, however
we also found that ER stress was suppressed, but autophagywas poten-
tiated and promoted programmednecrosis. Of note, Bax and Bak associ-
ate with, and are essential for IRE1α function at the ER membrane [75].
Indeed, ER stress generally activates Bax and Bak which in turn leads to
decreased mitochondrial membrane potential and mitochondria-
dependent apoptosis [72]. In the cells that lack Bax and Bak, formation
of mitochondrial permeability pores is thwarted, thus, preventing
apoptosome formation and activation of downstream executioner
caspases. This also makes the mitochondria more susceptible to sudden
rupture [76], and subsequent depletion of cellular ATP that can induce
necrosis due to deﬁcient energy stores [72]. This scenario appears to be
bourn out in our studies and contribute to excessive statin-induced cell
death, via necrosis. Collectively our data reveal the coordination of
apoptosis, autophagy and ER stress pathways in the face of mevalonate
cascade inhibition determines the death and/or survival response of
mesenchymal cells.
In summary, our ﬁndings demonstrate that autophagy holds a
protective function against apoptosis and ER-stress in human airway
ﬁbroblasts and smoothmuscle cells exposed to simvastatin. The impor-
tance role of the ER in cell response to mevalonate cascade inhibition
was evident by the fact that ER-activated caspase-4 is required for
simvastatin-induced cell death and apoptosis. Further, the ER
membrane anchored pro-apoptotic Bcl-2 family proteins, Bax and Bak,
mediatemevalonate cascade inhibition-induced ER stress and apoptosis
as the absence of these proteins is permissive for cell death by necrosis.
We provide evidence for the interconnection between apoptosis,
autophagy, and ER stress, and shed new light on some of the direct
cellular effects of statins that may be of relevance to the clinical use of
these compounds.
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